Synthesis of (IR)-[3,5-Bis(trifluoromethyl)phenyl] Ethanol
3445
Tsou, N. N.; Tattersall, D.; Rupniak, N. M. J.; Williams, A. R.; Rycroft, W. Struc-
tural optimization affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-
3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine,
a potent,
orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J.
Med. Chem. 1998, 41, 4607–4614; (c) Hale, J. J.; Mills, S. G.; MacCoss, M.;
Shah, S. K.; Qi, H.; Mathre, D.; Cascieri, M. A.; Sadwoski, S.; Strader, C.;
MacIntyre, D. E.; Metzer, J. M. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-
phenyl-4-((3-oxo-l,2,4-triazol-5-yl)methyl)morpholine (1):
A potent, orally
active, morpholine-based human Neurokinin-1 receptor antagonist. J. Med.
Chem. 1996, 39, 1760–1762.
4. (a) Zhao, M. M.; McNamara, J. M.; Ho, G. J.; Emerson, K. M.; Song, Z. J.;
Tschaen, D. M.; Brands, K. M. J.; Dolling, U. H.; Grabosk, E. J. J.; Reider, P. J.
Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antag-
onist, via a stereoselective lewis acid-catalyzed trans acetalization reaction. J. Org.
Chem. 2002, 67, 6743–6747; (b) Brands, K. M. J.; Payack, J. F.; Rosen, J. D.;
Nelson, T. D.; Candelario, A.; Huffman, M. A.; Zhao, M. M.; Li, J.; Crig, B.;
Song, Z. J.; Tschaen, D. M.; Harisen, K. J.; Devine, P. N.; Pye, P. J.;
Rossen, K.; Dormer, P. G.; Reamer, R. A.; Welch, C. J.; Mathre, D. J.;
Tsou, N. N.; McNamara, J. M.; Reider, P. J. Efficient synthesis of NK1 receptor
antagonist aprepitant using a crystallization-induced diastereoselective transform-
ation. J. Am. Chem. Soc. 2003, 125, 2129–2135; (c) Dorn, C. P.; Finke, P. E.;
Hale, J. J.; Gills, S. G.; Williams, B. J. Morpholine and thiomorpholine tachykinin
receptor antagonists. US 5,719,147; (d) Brands, K. M. J.; Krska, S. W.; Rosner, T.;
Conrad, K. M.; Corley, E. G.; Kaba, M.; Larsen, R. D.; Reamer, R. A.; Sun, Y.;
Tsay, F. Understanding the origin of unusual stepwise hydrogenation kinetics in
the synthesis of the 3-(4-fluorophenyl)morpholine moiety of NK1 receptor antag-
onist aprepitant. Org. Proc. Res. & Dev. 2006, 10, 109–117.
5. Hansen, K. B.; Chilenski, J. R.; Desmond, R.; Devine, P. N.; Grabowski, E. J. J.;
Heid, R.; Kubryk, M.; Mathre, D. J.; Varsolona, R. Scalable, efficient process for
the synthesis of (R)-3,5-bistrifluoromethylphenyl ethanol via catalytic asymmetric
transfer hydrogenation and isolation as a DABCO inclusion complex. Tetrahedron
Asymm. 2003, 14, 3581–3587.
6. International Conference on Harmonization of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICIH), Section Q3B: Guidelines on
Impurities in New Drug Products via Food and Drug Administration (FDA);
web site- http:// www.fda.gov/cder/guidance/1317fnl.pdf.
7. Homann, M. J.; Vail, R. B.; Previte, E.; Tamarez, M.; Morgan, B.; Dodds, D.;
Zaks, A. Rapid identification of enantioselective ketone reductions using
targeted microbial libraries. Tetrahedron 2004, 60, 789–797.
8. (a) Bornscheuer, U. T.; Kazlauskas, R. J. Hydrolase in Organic Synthesis Regio-
and Stereoselective Biotransformation; Wiley-VCH: Weinheim, 1999;
(b) Lieses, A.; Seelbach, K.; Wandrey, C. Industrial Biotransformation; Wiley-
VCH: Weinheim, 2000; (c) Faber, K. Biotransformation in Organic Chemistry,
4th ed.; Springer: Ber, 2000.
9. (a) Matsuda, T.; Tsuji, K.; Kamitanaka, T.; Harada, T.; Nakamura, K.; Ikariya, T.
Rate enhancement of lipase-catalyzed reaction in supercritical carbon dioxide.
Chem. Lett. 2005, 34, 1102–1103; (b) Dax, T.; Stanek, M.; Poechlauer, P. WO
2005095628 Al.; (c) Daiwang, X.; Zuyi, L. Shengming, M. Novozym-435-
catalyzed enzymatic separation of racemic propargylic alcohols. A facile route
to optically active terminal aryl propargylic alcohols. Tetrahedron Lett. 2003,
44, 6343–6346.